FUJIFILM Cellular Dynamics Announces License Agreement with Tome Biosciences for the Development of iPSC-Derived Cell Therapies.
MADISON, WIS., June 5, 2024 -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), announced today that it has entered an agreement to grant Tome Biosciences, Inc. (“Tome”), the programmable genomic integration (PGI) company, a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies.
Under the agreement, Tome will have a non-exclusive license to use the iPSC cell lines for research and development purposes, and to utilize GMP-grade cell lines for manufacturing and commercialization of iPSC-derived cell therapies.
Over the past few years FUJIFILM Cellular Dynamics has licensed its iPSC platform to numerous leading biotech companies including Novo A/S, Sana Biotechnology, IASO Biotherapeutics, Cynata Therapeutics among others.
#iPSC #StemCells #CellTherapies
Scientific Director at Caring Cross
3wWonderful team and wonderful to be working with Tome here at Caring Cross!